興業科技(002674.SZ):捐款200萬元用於抗擊新型冠狀病毒感染肺炎
格隆匯2月3日丨興業科技(002674.SZ)公佈,目前新型冠狀病毒感染肺炎引發全國人民關注,全國人民都在全力抗擊疫情。根據目前情況,醫療物資和防護資源缺口仍然較大。公司作為公眾上市公司,願切實履行社會責任,為抗擊疫情做貢獻。
公司於2020年1月28日以通訊表決的形式召開第五屆董事會第二次臨時會議,審議通過了《關於捐款人民幣200萬元用於抗擊新型冠狀病毒感染肺炎的議案》,同意公司向晉江市安海慈善協會捐款人民幣200萬元專項基金,此次捐款將用於新型冠狀病毒感染肺炎的抗擊和防治工作,包括但不限於藥品、醫療用品、口罩、防護服、消毒液、護目鏡等急需物資的採購等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.